Advancements in the development of antivirals against SARS-Coronavirus
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) caused an outbreak in 2002-2003, spreading to 29 countries with a mortality rate of about 10%. Strict quarantine and infection control methods quickly stopped the spread of the disease. Later research showed that SARS-CoV came from animals (zo...
Saved in:
Main Authors: | Mrityunjay Kumar, Mirza Sarwar Baig, Kanchan Bhardwaj |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Cellular and Infection Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1520811/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants
by: Jaehyeon Hwang, et al.
Published: (2025-01-01) -
Antivirals for the treatment of mild and moderate COVID-19 in South Africa
by: R Perumal, et al.
Published: (2023-12-01) -
p97 Inhibitors Possessing Antiviral Activity Against SARS-CoV-2 and Low Cytotoxicity
by: Rui Ding, et al.
Published: (2025-01-01) -
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)Research in context
by: Podjanee Jittamala, et al.
Published: (2025-02-01) -
Isothermal Evaporation Rate of Deposited Liquid Aerosols and the SARS-CoV-2 Coronavirus Survival
by: Pavel S. Grinchuk, et al.
Published: (2020-11-01)